HC Wainwright set a $8.00 price objective on CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) in a research note released on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
“We also note that Namodenoson has both Track status in the hepatocellular carcinoma (HCC) indication. Namodenoson could be approved based on this study. The trial is a Phase 2 study, but given the unmet medical need, if the data is strong enough, it could be used as a registrational study. For this reason and for ethical reasons, management has been advised not to alter the original study design (statistical plan).”,” the firm’s analyst commented.
CAN-FITE BIOPHA/S stock opened at $1.29 on Wednesday. CAN-FITE BIOPHA/S has a 12 month low of $1.12 and a 12 month high of $2.75.
CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) last released its quarterly earnings data on Friday, August 31st. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $2.00 million. CAN-FITE BIOPHA/S had a negative return on equity of 57.94% and a negative net margin of 2,453.03%.
CAN-FITE BIOPHA/S Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Read More: Do stock splits help investors?
Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with MarketBeat.com's FREE daily email newsletter.